Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ELVNVery BullishResearch Analysisnews

High materiality9/10

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

Jan 8, 2026, 2:36 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The strong initial results from the ENABLE trial create favorable market sentiment. Historical examples show similar efficacy announcements lead to substantial stock price increases.

AI summary

What happened, with direct paths to the underlying reporting

ELVN shares surge 50.42%, trading at $23.27. Phase 1b ENABLE trial shows strong efficacy for ELVN-001 in CML. 38% MMR and 16% DMR rates in 80 mg cohort; 53% MMR in 60 mg cohort. No new safety signals observed; favorable safety profile maintained. Phase 3 ENABLE-2 trial set to begin in second half of 2026.

ELVN shares surge 50.42%, trading at $23.27.
Phase 1b ENABLE trial shows strong efficacy for ELVN-001 in CML.
38% MMR and 16% DMR rates in 80 mg cohort; 53% MMR in 60 mg cohort.
No new safety signals observed; favorable safety profile maintained.
Phase 3 ENABLE-2 trial set to begin in second half of 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

William Blair Initiates Coverage on ELVN, Sees ELVN-001 as CML Disruptor